The Technology Metamorphosis: How We Grow from Here
The lines between technology and other parts of the economy are blurring and challenging incumbents and investors to keep up or fall behind
While big-name pharma attracted the most attention during COVID-19, says Portfolio Manager Sheetal Prasad, a handful of lesser-known life sciences tools & services providers are reinventing the historical model of drug discovery and development.
Any projections or forecasts presented herein are subject to change without notice. Actual data will vary and may not be reflected here. No liability whatsoever is accepted for any loss (whether direct, indirect, or consequential) that may arise from any use of the information contained in or derived from this material. Jennison may make investment decisions that are inconsistent with the recommendations or views expressed herein.